Neurology · Pain ManagementRegulatory Approvalregulatorymid-term

FDA Approves Supplement for Butalbital, Aspirin, Caffeine, and Codeine Phosphate

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 6:32:37 AM

Assessment confidence: 56% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's approval of the supplemental application for this combination product is significant as it strengthens LGM Pharma's competitive position in the pain management sector. Portfolio teams must evaluate the implications for market dynamics and competitor strategies in response to this approval. Regulatory context from FDA (FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)) supports the near-term read. Assessment grounded in 6 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for combination analgesics and consider strategic positioning. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 1 regulatory and 2 competitive items passed relevance filtering for LGM Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance LGM Pharma's position in the pain management market, potentially impacting competitors with similar formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL) (FDA). Entity match (lgm pharma). The approval indicates compliance with FDA standards, which may influence future submissions and regulatory strategies for similar combination products.

Key Risks

Elevated medium regulatory exposure for LGM Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval could lead to increased market share for LGM Pharma, potentially affecting revenue streams for competitors with similar analgesic products.
Portfolio teams should assess the competitive landscape for combination analgesics and consider strategic positioning.

What Would Change This Assessment

This becomes more urgent if Monitor market uptake and any subsequent competitive responses from other analgesic manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (lgm pharma)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute caffeine ingestion combined with post-activation potentiation enhancement on the anaerobic capacity of male collegiate basketball players.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

LGM Pharma
competitors with similar formulations

Commercial impact

medium

This approval could lead to increased market share for LGM Pharma, potentially affecting revenue streams for competitors with similar analgesic products.

Regulatory impact

medium

The approval indicates compliance with FDA standards, which may influence future submissions and regulatory strategies for similar combination products.

What to watch

Monitor market uptake and any subsequent competitive responses from other analgesic manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.